Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma

被引：47

作者：

Antonini, Giovanni

Cox, Maria Cristina

Montefusco, Enrico

Ferrari, Antonella

Conte, Esmeralda

Morino, Stefania

Latino, Pamela

Trasimeni, Guido

Monarca, Bruno

机构：

[1] Univ Roma La Sapienza, Sch Med 2, Dept Neurol Sci, Rome, Italy

[2] Univ Roma La Sapienza, Sch Med 2, Dept Cellular Biotechnol & Hematol, Rome, Italy

来源：

JOURNAL OF NEURO-ONCOLOGY | 2007年 / 81卷 / 02期

关键词：

intrathecal Rituximab; leptomeningeal lymphoma;

D O I：

10.1007/s11060-006-9217-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

A patient with relapsed B cell non-Hodgkin lymphoma (NHL) infiltrating the Central nervous system (CNS) and resistant to chemotherapy was treated with intrathecal Rituximab (IT RTX), administered weekly for eight weeks at increasing doses, from 10 to 40 mg. After the second administration the patient showed significant clinical improvement and Cerebro spinal fluid (CSF) clearance of lymphomatous cells. A MRI scan performed after 30 days from the start of therapy showed full regression of lymphomatous infiltration. This report confirms the efficacy and safety of IT RTX in the treatment of CNS B-cell NHL.

引用

收藏

页码：197 / 199

页数：3

相关论文

共 11 条

[1]

PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA [J].

FINE, HA ;

MAYER, RJ .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (11) :1093-1104

[2]

Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma [J].

Harjunpää, A ;

Wiklund, T ;

Collan, J ;

Janes, R ;

Rosenberg, J ;

Lee, D ;

Grillo-López, A ;

Meri, S .

LEUKEMIA & LYMPHOMA, 2001, 42 (04) :731-738

[3]

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology [J].

Hegde, U ;

Filie, A ;

Little, RF ;

Janik, JE ;

Grant, N ;

Steinberg, SM ;

Dunleavy, K ;

Jaffe, ES ;

Abati, A ;

Stetler-Stevenson, M ;

Wilson, WH .

BLOOD, 2005, 105 (02) :496-502

[4]

Recent advances in primary CNS lymphoma [J].

Hoang-Xuan, K ;

Camilleri-Broët, S ;

Soussain, C .

CURRENT OPINION IN ONCOLOGY, 2004, 16 (06) :601-606

[5]

Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

[6]

Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab [J].

Pels, H ;

Schulz, H ;

Manzke, O ;

Hom, E ;

Thall, A ;

Engert, A .

JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (03) :213-216

[7]

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment [J].

Rubenstein, JL ;

Combs, D ;

Rosenberg, J ;

Levy, A ;

McDermott, M ;

Damon, L ;

Ignoffo, R ;

Aldape, K ;

Shen, A ;

Lee, D ;

Grillo-Lopez, A ;

Shuman, MA .

BLOOD, 2003, 101 (02) :466-468

[8]

Schulz H, 2004, HAEMATOLOGICA, V89, P753

[9]

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma [J].

van Besien, K ;

Ha, CS ;

Murphy, S ;

McLaughlin, P ;

Rodriguez, A ;

Amin, K ;

Forman, A ;

Romaguera, J ;

Hagemeister, F ;

Younes, A ;

Bachier, C ;

Sarris, A ;

Sobocinski, KS ;

Cox, JD ;

Cabanillas, F .

BLOOD, 1998, 91 (04) :1178-1184

[10]

Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab [J].

Watanabe N. ;

Takahashi T. ;

Sugimoto N. ;

Tanaka Y. ;

Kurata M. ;

Matsushita A. ;

Maeda A. ;

Nagai K. ;

Nasu K. .

International Journal of Clinical Oncology, 2005, 10 (5) :357-361